ReP USP - Resultado da busca

Filtros : "ANGIOTENSINAS" "FM-MDR" Limpar

Filtros

USP affiliated authors
- bassaneze, vinícius (1)
- chammas, roger (1)
- fernandes, tiago (1)
- fujihara, clarice kazue (1)
- krieger, jose eduardo (1)

Artigo de periodico
High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity (2021)
Magalhães, Flávio Castro ; Fernandes, Tiago ; Bassaneze, Vinicius; Mattos, Katt Coelho; Schettert, Isolmar; Marques, Fabio Luiz Navarro ; Krieger, Jose Eduardo ; Nava, Roberto; Barauna, Valério Garrone; Oliveira, Edilamar Menezes de
Source: Clinical Science. Unidades: EEFE, FM
Subjects: ANGIOTENSINAS, SISTEMA RENINA-ANGIOTENSINA, ERITROPOIETINA, TREINAMENTO FÍSICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAGALHÃES, Flávio Castro et al. High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity. Clinical Science, v. 135, n. 20, p. 2377-2391, 2021Tradução . . Disponível em: https://doi.org/10.1042/CS20210739. Acesso em: 15 nov. 2024.
APA
Magalhães, F. C., Fernandes, T., Bassaneze, V., Mattos, K. C., Schettert, I., Marques, F. L. N., et al. (2021). High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity. Clinical Science, 135( 20), 2377-2391. doi:10.1042/CS20210739
NLM
Magalhães FC, Fernandes T, Bassaneze V, Mattos KC, Schettert I, Marques FLN, Krieger JE, Nava R, Barauna VG, Oliveira EM de. High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity [Internet]. Clinical Science. 2021 ; 135( 20): 2377-2391.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1042/CS20210739
Vancouver
Magalhães FC, Fernandes T, Bassaneze V, Mattos KC, Schettert I, Marques FLN, Krieger JE, Nava R, Barauna VG, Oliveira EM de. High-volume endurance exercise training stimulates hematopoiesis by increasing ACE NH2-terminal activity [Internet]. Clinical Science. 2021 ; 135( 20): 2377-2391.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1042/CS20210739
Artigo de periodico
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma (2010)
Otake, Andréia Hanada; Mattar, Ana Lucia; Freitas, Helano Carioca; Machado, Camila Maria Longo; Nonogaki, Suely; Fujihara, Clarice Kazue; Zatz, Roberto; Chammas, Roger
Source: Cancer Chemotherapy and Pharmacology. Unidade: FM
Subjects: ANGIOTENSINAS, MELANOMA, MODELOS ANIMAIS, FATORES DE CRESCIMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OTAKE, Andréia Hanada et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemotherapy and Pharmacology, v. 66, n. 1, p. 79-87, 2010Tradução . . Disponível em: https://doi.org/10.1007/s00280-009-1136-0. Acesso em: 15 nov. 2024.
APA
Otake, A. H., Mattar, A. L., Freitas, H. C., Machado, C. M. L., Nonogaki, S., Fujihara, C. K., et al. (2010). Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemotherapy and Pharmacology, 66( 1), 79-87. doi:10.1007/s00280-009-1136-0
NLM
Otake AH, Mattar AL, Freitas HC, Machado CML, Nonogaki S, Fujihara CK, Zatz R, Chammas R. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma [Internet]. Cancer Chemotherapy and Pharmacology. 2010 ; 66( 1): 79-87.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s00280-009-1136-0
Vancouver
Otake AH, Mattar AL, Freitas HC, Machado CML, Nonogaki S, Fujihara CK, Zatz R, Chammas R. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma [Internet]. Cancer Chemotherapy and Pharmacology. 2010 ; 66( 1): 79-87.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s00280-009-1136-0

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024